HealthEquity, Inc. (HQY) Cash Flow Statement
Where HQY’s cash came from and went, FY2026
January 31, 2026 · U.S. dollars- Cash from operations
- $457.1M +34.5% vs FY2025
- Capital expenditures
- $2.0M 0.1% of revenue
- Free cash flow
- $455.1M 34.7% margin
- Returned to shareholders
- $299.3M 66% of free cash flow
- Change in cash
- $23.0M cash at year-end $318.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
HQY operating cash flow, capex and free cash flow
HQY cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $45.6MFY2017 | $457.1MFY2026 | +29.2%/yr | |
| Capital expenditures | $12.7MFY2017 | $2.0MFY2026 | −18.7%/yr | |
| Free cash flow | $32.9MFY2017 | $455.1MFY2026 | +33.9%/yr | |
| Free cash flow margin | 18.5%FY2017 | 34.7%FY2026 | +16.2 pts | |
| Operating cash flow / net income | 1.73FY2017 | 2.12FY2026 | +0.40 | |
| Stock-based compensation | $8.4MFY2017 | $73.1MFY2026 | +27.2%/yr | |
| Dividends paid | $0FY2017 | $0FY2018 | — | |
| Share buybacks (net) | $0FY2017 | $299.3MFY2026 | — | |
| Capex / revenue | 7.1%FY2017 | 0.1%FY2026 | −7.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
HQY cash flow by activity
HQY net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
HQY cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $215.2M | $96.7M | $55.7M | −$26.1M | −$44.3M | $8.8M | $39.7M | $73.9M | $47.4M | $26.4M |
| Depreciation & amortization | $154.7M | $162.5M | $153.1M | $161.2M | $137.2M | $115.9M | $55.4M | $18.2M | $16.0M | $13.2M |
| Stock-based compensation | $73.1M | $96.4M | $77.2M | $62.6M | $52.8M | $42.9M | $39.8M | $21.1M | $14.3M | $8.4M |
| Change in working capital | −$26.6M | −$6.5M | −$33.1M | −$33.4M | $1.6M | $12.3M | −$9.5M | −$1.3M | −$448,000 | $419,000 |
| Other non-cash items | $40.8M | −$9.2M | −$10.0M | −$13.7M | −$6.3M | $1.7M | −$19.5M | $1.6M | $4.5M | −$2.8M |
| Cash from operating activities | $457.1M | $339.9M | $242.8M | $150.7M | $141.0M | $181.6M | $105.9M | $113.4M | $81.7M | $45.6M |
| Investing activities | ||||||||||
| Capital expenditures | −$2.0M | −$2.1M | −$46.1M | −$119.1M | −$137.1M | −$97.0M | −$42.1M | −$15.0M | −$33.4M | −$12.7M |
| Investments (net) | $1.6M | −$505.5M | −$46.1M | −$119.1M | $2.4M | −$97.0M | −$53.8M | $40.7M | −$483,000 | −$379,000 |
| Acquisitions & other investing | −$46.8M | $2.1M | $46.1M | $119.1M | −$504.5M | $97.0M | −$1.65B | $0 | −$2.9M | $0 |
| Cash from investing activities | −$47.1M | −$505.5M | −$46.1M | −$119.1M | −$639.2M | −$97.0M | −$1.74B | $25.7M | −$36.7M | −$13.1M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share repurchases & issuance (net) | −$299.3M | −$121.5M | $0 | $0 | — | $295.3M | $469.8M | $22.9M | $14.6M | $7.1M |
| Net borrowing (repayment) | −$100.0M | $175.0M | −$54.4M | −$8.8M | −$53.1M | −$239.1M | $1.21B | $1.24B | $1.24B | $1.24B |
| Shares issued | $0 | $0 | $0 | $0 | $456.6M | $286.8M | $458.5M | $0 | $0 | $0 |
| Other financing | $12.3M | $4.1M | $7.3M | $6.1M | −$8.7M | −$290.6M | −$672.3M | −$1.24B | −$1.24B | −$1.23B |
| Cash from financing activities | −$387.0M | $57.6M | −$47.0M | −$2.7M | $394.9M | $52.4M | $1.47B | $22.9M | $14.6M | $23.8M |
| Summary | ||||||||||
| Net change in cash | $23.0M | −$108.0M | $149.7M | $28.9M | −$103.4M | $137.1M | −$169.7M | $162.0M | $59.5M | $56.3M |
| Cash at end of period | $318.9M | $295.9M | $404.0M | $254.3M | $225.4M | $328.8M | $191.7M | $361.5M | $199.5M | $140.0M |
| Free cash flow | $455.1M | $337.8M | $196.8M | $31.5M | $3.9M | $84.7M | $63.8M | $98.4M | $48.3M | $32.9M |
| Free cash flow margin | 34.7% | 28.2% | 19.7% | 3.7% | 0.5% | 11.5% | 12.0% | 34.2% | 21.1% | 18.5% |
| Capex / revenue | 0.1% | 0.2% | 4.6% | 13.8% | 18.1% | 13.2% | 7.9% | 5.2% | 14.5% | 7.1% |
| Operating cash flow / net income | 2.12 | 3.51 | 4.36 | — | — | 20.56 | 2.67 | 1.53 | 1.73 | 1.73 |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $65.6M | $69.4M | $49.7M | $51.7M | $59.9M | $53.9M | $26.4M | $5.7M | $35.8M | $28.8M | $26.4M | $14.7M |
| Depreciation & amortization | $42.0M | $38.2M | $38.7M | $38.8M | $38.5M | $38.7M | $39.2M | $40.7M | $43.6M | $38.9M | $37.9M | $37.8M |
| Stock-based compensation | $22.2M | $19.4M | $19.1M | $20.5M | $19.1M | $14.3M | $21.7M | $21.1M | $21.6M | $32.0M | $17.2M | $21.7M |
| Change in working capital | −$3.2M | −$39.7M | $13.1M | $15.3M | −$11.2M | −$43.8M | −$9.0M | $25.9M | $6.2M | −$29.7M | −$7.0M | −$9.9M |
| Other non-cash items | $9.5M | $10.2M | −$2.7M | $12.3M | $29.7M | $1.6M | −$2.5M | −$2.9M | $909,000 | −$4.7M | $2.6M | −$7.1M |
| Cash from operating activities | $136.2M | $97.5M | $117.9M | $138.6M | $135.9M | $64.7M | $75.7M | $90.5M | $108.1M | $65.4M | $77.1M | $57.1M |
| Investing activities | ||||||||||||
| Capital expenditures | −$978,000 | −$362,000 | −$16.4M | −$784,000 | −$15.3M | −$16.1M | −$13.6M | −$12.9M | −$209.1M | −$269.9M | −$11.3M | −$15.4M |
| Investments (net) | −$10.1M | $2.4M | — | — | −$11.2M | −$16.1M | −$13.6M | −$12.9M | −$209.1M | −$269.9M | −$11.3M | −$15.4M |
| Acquisitions & other investing | −$14.8M | −$15.9M | $7.9M | −$10.6M | $15.3M | $16.1M | $13.6M | $12.9M | $209.1M | $269.9M | $11.3M | $15.4M |
| Cash from investing activities | −$25.9M | −$13.9M | −$8.4M | −$11.4M | −$11.2M | −$16.1M | −$13.6M | −$12.9M | −$209.1M | −$269.9M | −$11.3M | −$15.4M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | −$107.7M | −$123.3M | −$81.0M | −$92.4M | −$66.7M | −$59.1M | −$63.0M | −$58.5M | $0 | $0 | — | — |
| Net borrowing (repayment) | −$11.9M | −$15.0M | −$25.0M | −$25.0M | −$50.0M | $0 | −$25.0M | −$25.0M | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $5,000 | $1.1M | $6.2M | −$5.0M | $8.6M | $2.4M | −$426,000 | $1.1M | $176.6M | $51.8M | $4.1M | $2.0M |
| Cash from financing activities | −$119.6M | −$137.2M | −$99.8M | −$122.4M | −$108.1M | −$56.6M | −$88.4M | −$82.4M | $176.6M | $51.8M | $4.1M | $2.0M |
| Summary | ||||||||||||
| Net change in cash | −$9.4M | −$53.6M | $9.7M | $4.8M | $16.6M | −$8.1M | −$26.2M | −$4.7M | $75.7M | −$152.8M | $69.9M | $43.7M |
| Cash at end of period | $256.0M | $265.4M | $318.9M | $309.3M | $304.5M | $287.9M | $295.9M | $322.2M | $326.9M | $251.2M | $404.0M | $334.1M |
| Free cash flow | $135.2M | $97.2M | $101.5M | $137.8M | $151.2M | $48.6M | $62.2M | $77.7M | −$101.0M | −$204.5M | $65.8M | $41.7M |
| Free cash flow margin | 38.5% | 27.4% | 30.3% | 42.8% | 46.4% | 14.7% | 19.9% | 25.9% | −33.7% | −71.1% | 25.1% | 16.7% |
| Capex / revenue | 0.3% | 0.1% | 4.9% | 0.2% | 4.7% | 4.9% | 4.3% | 4.3% | 69.7% | 93.9% | 4.3% | 6.2% |
| Operating cash flow / net income | 2.07 | 1.40 | 2.37 | 2.68 | 2.27 | 1.20 | 2.87 | 15.88 | 3.02 | 2.27 | 2.92 | 3.89 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
HQY cash generation
In fiscal 2026 (ended January 31, 2026), HealthEquity generated $457.1 million of cash from operations (up 34.5%) and spent $2.0 million on capital expenditures, leaving free cash flow of $455.1 million, 34.7% of revenue. It returned $299.3 million to shareholders through dividends ($0) and net share buybacks ($299.3 million). Cash and equivalents rose by $23.0 million over the year.
Related: HQY income statement, HQY balance sheet. See the HQY stock overview for the latest quote and news.
HQY cash flow FAQ
What is HealthEquity's free cash flow?
HealthEquity's free cash flow was $455.1 million in fiscal 2026: $457.1 million of operating cash flow minus $2.0 million of capital expenditures It was $337.8 million a year earlier..
How much cash does HealthEquity generate from operations?
HealthEquity generated $457.1 million of cash from operating activities in fiscal 2026, 2.12 times its net income of $215.2 million.
How much does HealthEquity spend on capital expenditures?
HealthEquity spent $2.0 million on capital expenditures in fiscal 2026, 0.1% of revenue, compared with $2.1 million the year before.
How much stock does HealthEquity buy back?
HealthEquity spent $299.3 million on net share repurchases in fiscal 2026.